Cargando…

Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain

Chronic pain is a common detrimental condition that affects around 20% of the world population. The current drugs to treat chronic pain states, especially neuropathic pain, have a limited clinical efficiency and present significant adverse effects that complicates their regular use. Recent studies h...

Descripción completa

Detalles Bibliográficos
Autores principales: Lara, César O., Burgos, Carlos F., Moraga-Cid, Gustavo, Carrasco, Mónica A., Yévenes, Gonzalo E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079299/
https://www.ncbi.nlm.nih.gov/pubmed/32218730
http://dx.doi.org/10.3389/fphar.2020.00167
_version_ 1783507795740459008
author Lara, César O.
Burgos, Carlos F.
Moraga-Cid, Gustavo
Carrasco, Mónica A.
Yévenes, Gonzalo E.
author_facet Lara, César O.
Burgos, Carlos F.
Moraga-Cid, Gustavo
Carrasco, Mónica A.
Yévenes, Gonzalo E.
author_sort Lara, César O.
collection PubMed
description Chronic pain is a common detrimental condition that affects around 20% of the world population. The current drugs to treat chronic pain states, especially neuropathic pain, have a limited clinical efficiency and present significant adverse effects that complicates their regular use. Recent studies have proposed new therapeutic strategies focused on the pharmacological modulation of G-protein-coupled receptors, transporters, enzymes, and ion channels expressed on the nociceptive pathways. The present work intends to summarize recent advances on the pharmacological modulation of pentameric ligand-gated ion channels, which plays a key role in pain processing. Experimental data have shown that novel allosteric modulators targeting the excitatory nicotinic acetylcholine receptor, as well as the inhibitory GABA(A) and glycine receptors, reverse chronic pain-related behaviors in preclinical assays. Collectively, these evidences strongly suggest the pharmacological modulation of pentameric ligand-gated ion channels is a promising strategy towards the development of novel therapeutics to treat chronic pain states in humans.
format Online
Article
Text
id pubmed-7079299
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70792992020-03-26 Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain Lara, César O. Burgos, Carlos F. Moraga-Cid, Gustavo Carrasco, Mónica A. Yévenes, Gonzalo E. Front Pharmacol Pharmacology Chronic pain is a common detrimental condition that affects around 20% of the world population. The current drugs to treat chronic pain states, especially neuropathic pain, have a limited clinical efficiency and present significant adverse effects that complicates their regular use. Recent studies have proposed new therapeutic strategies focused on the pharmacological modulation of G-protein-coupled receptors, transporters, enzymes, and ion channels expressed on the nociceptive pathways. The present work intends to summarize recent advances on the pharmacological modulation of pentameric ligand-gated ion channels, which plays a key role in pain processing. Experimental data have shown that novel allosteric modulators targeting the excitatory nicotinic acetylcholine receptor, as well as the inhibitory GABA(A) and glycine receptors, reverse chronic pain-related behaviors in preclinical assays. Collectively, these evidences strongly suggest the pharmacological modulation of pentameric ligand-gated ion channels is a promising strategy towards the development of novel therapeutics to treat chronic pain states in humans. Frontiers Media S.A. 2020-03-03 /pmc/articles/PMC7079299/ /pubmed/32218730 http://dx.doi.org/10.3389/fphar.2020.00167 Text en Copyright © 2020 Lara, Burgos, Moraga-Cid, Carrasco and Yévenes http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lara, César O.
Burgos, Carlos F.
Moraga-Cid, Gustavo
Carrasco, Mónica A.
Yévenes, Gonzalo E.
Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain
title Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain
title_full Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain
title_fullStr Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain
title_full_unstemmed Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain
title_short Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain
title_sort pentameric ligand-gated ion channels as pharmacological targets against chronic pain
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079299/
https://www.ncbi.nlm.nih.gov/pubmed/32218730
http://dx.doi.org/10.3389/fphar.2020.00167
work_keys_str_mv AT laracesaro pentamericligandgatedionchannelsaspharmacologicaltargetsagainstchronicpain
AT burgoscarlosf pentamericligandgatedionchannelsaspharmacologicaltargetsagainstchronicpain
AT moragacidgustavo pentamericligandgatedionchannelsaspharmacologicaltargetsagainstchronicpain
AT carrascomonicaa pentamericligandgatedionchannelsaspharmacologicaltargetsagainstchronicpain
AT yevenesgonzaloe pentamericligandgatedionchannelsaspharmacologicaltargetsagainstchronicpain